Idera/Merck KGaA TLR9 Misses Mark In RCC
This article was originally published in The Pink Sheet Daily
Executive Summary
Monotherapy fails; Merck pursuing IMO-2055 as combo therapy.
You may also be interested in...
Guidance To Cut Diabetes Drug CV Risk Gets First Test With Pending NDAs
FDA’s flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late-stage development.
Guidance To Cut Diabetes Drug CV Risk Gets First Test With Pending NDAs
FDA’s flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late-stage development.
Merck KGaA Joins Rush To Develop Toll-Like Receptor 9 Agonists
Company signed a deal with Idera valued at $421 million, gaining two of its lead TLR9 candidates for oncology indications, excluding vaccines.